慢性淋巴细胞白血病患者中的单核细胞髓系来源抑制细胞：单中心经验。
Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience.
机构信息
Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Department of Internal Medicine, Clinical Hematology Unit, Faculty of Medicine, Assiut University, Assiut, Egypt.
出版信息
Leuk Lymphoma. 2020 Jul;61(7):1645-1652. doi: 10.1080/10428194.2020.1728747. Epub 2020 Feb 20.
This study aimed to analyze the frequency of peripheral Mo-myeloid-derived suppressor cells (Mo-MDSCs) in newly diagnosed CLL patients and to correlate their level with other prognostic factors such as frequency of CD38 cells and ZAP-70 cells and with the clinical response and survival outcomes in these patients. Fifty CLL patients and 20 age-matched healthy controls were included in this study. Flow cytometric detection of ZAP 70, CD38, and Mo-MDSCs was done. Mo-MDSC levels wer significantly higher in CLL patients (27.51 ± 1.70) than healthy controls (16.79 ± 0.66; < .0001). Higher levels of Mo-MDSCs were detected in advanced Rai clinical staging than Stage I. Mo-MDSCs level was significantly correlated with the frequency of CD38 ( = 0.505; < .0001) and ZAP-70 cells ( = 0.421; < .0001). Higher levels of Mo-MDSCs predict poor survival in CLL patients with Mo-MDSCs levels <25% ( = 21) versus >25% ( = 29; log - Rank test, < .0001). In conclusion, Mo-MDSCs are correlated with tumor progression and a poor prognosis in CLL.
本研究旨在分析初诊 CLL 患者外周血髓系来源抑制细胞（Mo-MDSCs）的频率，并将其水平与其他预后因素（如 CD38 细胞和 ZAP-70 细胞的频率）以及这些患者的临床反应和生存结局相关联。本研究纳入了 50 例 CLL 患者和 20 名年龄匹配的健康对照者。采用流式细胞术检测 ZAP 70、CD38 和 Mo-MDSCs。CLL 患者的 Mo-MDSC 水平（27.51±1.70）明显高于健康对照组（16.79±0.66；<0.0001）。晚期 Rai 临床分期患者的 Mo-MDSC 水平高于Ⅰ期。Mo-MDSC 水平与 CD38 频率（ = 0.505；<0.0001）和 ZAP-70 细胞（ = 0.421；<0.0001）呈显著正相关。Mo-MDSC 水平较高预示着 CLL 患者的生存不良，Mo-MDSC 水平<25%（ = 21）的患者与>25%（ = 29）的患者相比（对数秩检验，<0.0001）。总之，Mo-MDSCs 与 CLL 中的肿瘤进展和不良预后相关。
Zotero 插件